EFPIA criticized the intent of the French government to broadly enlarge the use of off-label drugs for economic reasons, even if there is an approved drug available.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, today criticized the intent of the French government to broadly enlarge the use of-off label drugs for economic reasons, even if there is an approved drug available.
Yesterday (July 8) the French National Assembly voted the draft law proposal, which would potentially allow doctors to use off-label drugs even if there is an alternative drug approved. This draft law has still to be reviewed by the French Senate and a review by the French Constitutional Court is also possible.
The draft law specifically references a Roche cancer drug (Avastin) as an alternative eye treatment for wet age-related macular degeneration (AMD), an indication for which the drug is not approved and for which two authorized alternatives exist.
Speaking about this development Richard Bergström, EFPIA Director General, said: “A worrying trend is growing across Europe with governments bypassing important health safeguards and making public health decisions based purely on short-term economic considerations. This move is a material breach of the regulatory framework created to preserve the highest standard of patient safety in Europe.”
Bergström added: “This is a serious public health issue which the European Commission must address urgently before it becomes more widespread. EU Member States should not be creating secondary, national marketing authorizations for reasons that undermine the EU regulatory framework and could potentially put patients at risk, and deliver only short-term economic gains.”
Bergström concluded: “If public authorities continue to promote off-label use of other, less costly, medicines that have not undergone stringent safety and efficacy assessments, pharmaceutical companies will be discouraged from undergoing the costly and time-consuming authorisation process for new indications.”
EFPIA calls on the European Commission to ensure Member States adhere to the European regulatory framework and that financial considerations do not take precedence over the safety of patients.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.